Controversies in the management of regional nodes in melanoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 3, 2012, Pages 414-421

  Plitas, George ^a   Ariyan, Charlotte E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Lymph node dissection; Melanoma; Sentinel lymph node biopsy

Indexed keywords

CANCER SURGERY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; PATIENT SELECTION; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; TREATMENT INDICATION;

EID: 84858195303     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0038     Document Type: Review

References (87)

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
2. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 2009;17:976-983.
3. Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a "sentinel node" in cancer of the parotid. Cancer 1960;13:77-78.
4. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456-466. (Pubitemid 8063506)
5. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
6. Gershenwald JE, Ross MI. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 2011;364:1738-1745.
7. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996;223:217-224. (Pubitemid 26065217)
8. McMasters KM, Wong SL, Edwards MJ, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001;130:151-156. (Pubitemid 32721662)
9. Rousseau DL Jr, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003;10:569-574. (Pubitemid 40486922)
10. White RL Jr, Ayers GD, Stell VH, et al. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol 201118:3593-3600.
11. Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011;29:2199-2205.
12. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004;11:247-258. (Pubitemid 40486764)
13. Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol 2005;12:282-288. (Pubitemid 40616492)
14. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 2006;24:4464-4471. (Pubitemid 46630985)
15. Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001;233:250-258. (Pubitemid 32106080)
16. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-1317. (Pubitemid 44465459)
17. Thomas JM. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 2008;5:18-23. (Pubitemid 351512425)
18. Estourgie SH, Nieweg OE, Kroon BB. High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. Br J Surg 2004;91:1370-1371. (Pubitemid 39331464)
19. Thomas JM, Clark MA. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol 2004;30:686-691.
20. Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005;12:587-596. (Pubitemid 41126088)
21. van Poll D, Thompson JF, Colman MH, et al. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol 2005;12:597-608. (Pubitemid 41126089)
22. Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw 2009;7:308-317.
23. Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006;13:302-309. (Pubitemid 43255912)
24. Agnese DM, Abdessalam SF, Burak WE Jr, et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003;134:542-547; discussion 547-548.
25. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302-311; discussion 311-313.
26. Otley CC. Sentinel lymph node biopsy for melanoma-standard of care? Dermatol Surg 2000;26:1067-1069.
27. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 1988;6:163-172. (Pubitemid 18040005)
28. Ferrone CR, Panageas KS, Busam K, et al. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002;9:637-645. (Pubitemid 34857980)
29. Gutzmer R, Satzger I, Thoms KM, et al. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges 2008;6:198-203. (Pubitemid 351361065)
30. Meguerditchian AN, Asubonteng K, Young C, et al. Thick primary melanoma has a heterogeneous tumor biology: an institutional series. World J Surg Oncol 2011;9:40.
31. Scoggins CR, Bowen AL, Martin RC II, et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg 2010;145:622-627.
32. Harrist TJ, Rigel DS, Day CL Jr, et al. "Microscopic satellites" are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 1984;53:2183-2187. (Pubitemid 14101792)
33. Leon P, Daly JM, Synnestvedt M, et al. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991;126:1461-1468.
34. Kimsey TF, Cohen T, Patel A, et al. Microscopic satellitosis in patients with primary cutaneous melanoma: implications for nodal basin staging. Ann Surg Oncol 2009;16:1176-1183.
35. Yao KA, Hsueh EC, Essner R, et al. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg 2003;238:743-747. (Pubitemid 38182267)
36. Voit C, Van Akkooi AC, Schafer-Hesterberg G, et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. J Clin Oncol 2010;28:847-852.
37. Sanki A, Uren RF, Moncrieff M, et al. Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. J Clin Oncol 2009;27:5614-5619.
38. Rossi CR, Mocellin S, Scagnet B, et al. The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol 2003;83:80-84. (Pubitemid 36667415)
39. van Rijk MC, Teertstra HJ, Peterse JL, et al. Ultrasonography and fine-needle aspiration cytology in the preoperative evaluation of melanoma patients eligible for sentinel node biopsy. Ann Surg Oncol 2006;13:1511-1516. (Pubitemid 44749663)
40. Thompson JF, Haydu LE, Sanki A, Uren RF. Ultrasound assessment of lymph nodes in the management of early-stage melanoma. J Surg Oncol 2011;104:354-360.
41. Thompson JF, Haydu LE, Uren RF, et al. Preoperative ultrasound assessment of sentinel nodes in melanoma patients does not provide reliable staging: results from a large multicenter trial, Society of Surgical Oncology 64th Annual Cancer Symposium. Ann Surg Oncol 2011;18:1-144.
42. Stojadinovic A, Allen PJ, Clary BM, et al. Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma. Ann Surg 2002;235:92-98. (Pubitemid 34062404)
43. Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995;5:255-260.
44. Tanis PJ, Boom RP, Koops HS, et al. Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol 2001;8:222-226. (Pubitemid 32294802)
45. Scolyer RA, Thompson JF, McCarthy SW, et al. Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. J Am Coll Surg 2005;201:821-823; author reply 823-824.
46. Ariyan S, Ariyan C, Farber LR, et al. Reliability of identification of 655 sentinel lymph nodes in 263 consecutive patients with malignant melanoma. J Am Coll Surg 2004;198:924-932. (Pubitemid 38759843)
47. Alkhatib W, Hertzenberg C, Jewell W, et al. Utility of frozen-section analysis of sentinel lymph node biopsy specimens for melanoma in surgical decision making. Am J Surg 2008;196:827-832; discussion 832-833.
48. Soo V, Shen P, Pichardo R, et al. Intraoperative evaluation of sentinel lymph nodes for metastatic melanoma by imprint cytology. Ann Surg Oncol 2007;14:1612-1617. (Pubitemid 46790988)
49. Prieto VG. Use of frozen sections in the examination of sentinel lymph nodes in patients with melanoma. Semin Diagn Pathol 2008;25:112-115. (Pubitemid 351885455)
50. Scolyer RA, Murali R, McCarthy SW, Thompson JF. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol 2008;25:100-111. (Pubitemid 351885456)
51. Baisden BL, Askin FB, Lange JR, Westra WH. HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am J Surg Pathol 2000;24:1140-1146. (Pubitemid 30612836)
52. Gietema HA, Vuylsteke RJ, de Jonge IA, et al. Sentinel lymph node investigation in melanoma: detailed analysis of the yield from step sectioning and immunohistochemistry. J Clin Pathol 2004;57:618-620. (Pubitemid 38725763)
53. Spanknebel K, Coit DG, Bieligk SC, et al. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol 200529:305-317.
54. Wang X, Heller R, VanVoorhis N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768-774. (Pubitemid 24376375)
55. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998;280:1410-1415. (Pubitemid 28496047)
56. Takeuchi H, Taback B, Kuo C, Hoon DS. Clinicopathological utility of molecular staging for melanoma patients undergoing sentinel lymphadenectomy. Ann Surg Oncol 2004;11:152S-155S.
57. Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006;24:2849-2857. (Pubitemid 46630585)
58. Kammula US, Ghossein R, Bhattacharya S, Coit DG. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction-staged sentinel lymph nodes from melanoma patients. J Clin Oncol 2004;22:3989-3996. (Pubitemid 41079882)
59. Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol 2008;15:1566-1576.
60. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008;15:683-690.
61. Chao C, Wong SL, Ross MI, et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 2002;184:520-524; discussion 525.
62. Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010;17:3324-3329.
63. Ariyan C, Brady MS, Gonen M, et al. Positive nonsentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol 2009;16:186-190.
64. Ghaferi AA, Wong SL, Johnson TM, et al. Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. Ann Surg Oncol 2009;16:2978-2984.
65. Rossi CR, De Salvo GL, Bonandini E, et al. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol 2008;15:1202-1210.
66. Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 2006;13:809-816. (Pubitemid 43727365)
67. Kingham TP, Panageas KS, Ariyan CE, et al. Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. Ann Surg Oncol 2010;17:514-520.
68. Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 2004;11:162S-168S.
69. Younan R, Bougrine A, Watters K, et al. Validation study of the s classification for melanoma patients with positive sentinel nodes: the Montreal experience. Ann Surg Oncol 2010;17:1414-1421.
70. Fink AM, Weihsengruber F, Duschek N, et al. Value of micromorphometric criteria of sentinel lymph node metastases in predicting further nonsentinel lymph node metastases in patients with melanoma. Melanoma Res 2011;21:139-143.
71. Frankel TL, Griffith KA, Lowe L, et al. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma? Ann Surg Oncol 2008;15:2403-2411.
72. Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 2005;201:37-47. (Pubitemid 40840562)
73. Murali R, Desilva C, Thompson JF, Scolyer RA. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol 2010;28:4441-4449.
74. Agrawal S, Kane JM, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009;115: 5836-5844.
75. Rao NG, Yu HH, Trotti A III, Sondak VK. The role of radiation therapy in the management of cutaneous melanoma. Surg Oncol Clin N Am 2011;20:115-131.
76. Burmeister B, Henderson MA, Thompson JF et al. Adjuvant radiotherapy improves regional (lymph node field) control in melanoma patients after lymphadenectomy: results of an Intergroup randomized trial (TROG 02.01/ANZMTG 01.02). Int J Radiat Oncol Biol Phys 2009;75(Suppl 3):S2.
77. Guadagnolo BA, Zagars GK. Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanoma. Lancet Oncol 2009;10:409-416.
78. Burmeister BH, Smithers BM, Davis S, et al. Radiation therapy following nodal surgery for melanoma: an analysis of late toxicity. ANZ J Surg 2002;72:344-348. (Pubitemid 34535387)
79. Ballo MT, Zagars GK, Gershenwald JE, et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 2004;11:1079-1084. (Pubitemid 40486654)
80. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 2000;7:160-165. (Pubitemid 30164687)
81. Carlson GW, Murray DR, Hestley A, et al. Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it? Ann Surg Oncol 2003;10:408-415. (Pubitemid 40486939)
82. Jacobs IA, Chang CK, Salti GI. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma. Am Surg 2004;70:59-62.
83. Caraco C, Celentano E, Lastoria S, et al. Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters. Ann Surg Oncol 2004;11:198S-202S.
84. Reeves ME, Delgado R, Busam KJ, et al. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 2003;10:27-31.
85. Govindarajan A, Ghazarian DM, McCready DR, Leong WL. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol 2007;14:906-912. (Pubitemid 46175342)
86. Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 2008;26:4296-4303.
87. Van Akkooi AC, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive nodes. Ann Surg 2008;248:949-955.